Clinical Trials Directory

Trials / Terminated

TerminatedNCT03631680

The Role of Estrogen in Adipocyte Remodeling Following Surgical Menopause

Status
Terminated
Phase
Study type
Observational
Enrollment
2 (actual)
Sponsor
Pennington Biomedical Research Center · Academic / Other
Sex
Female
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

The overarching aim of this study is to assess the downstream effects of abrupt estrogen deficiency in women undergoing elective bilateral oophorectomy by studying: 1. the rate of in vivo adipogenesis in the subcutaneous abdominal (scABD) and subcutaneous femoral (scFEM) adipose tissue depots following bilateral oophorectomy surgery using an innovative (and tested) 8-week incorporation of stable isotope (deuterium; 2H) administered in the form of heavy water (2H2O) to endogenously label adipose tissue DNA; 2. the changes in expression of subcutaneous adipose tissue genes and proteins specific to adipocyte expansion and function; extracellular matrix remodeling and fibrosis; and inflammation in the scABD and scFEM depots before and after elective bilateral oophorectomy.

Detailed description

This is a cross-sectional study that will enroll up to 10 women undergoing laparoscopic, elective bilateral oophorectomy at a local hospital in Baton Rouge, LA. Women will complete 7 study visits over 3 months; a single screening visit to assess eligibility, a pre-bilateral oophorectomy visit for imaging and adipose tissue biopsy collection, and 5 post-bilateral oophorectomy visits to "dose", maintain compliance and subject retention, and perform follow-up imaging and adipose tissue biopsy collection for outcome measures.

Conditions

Interventions

TypeNameDescription
PROCEDUREBilateral Oophorectomy SurgeryWomen undergoing elective, laparoscopic bilateral oophorectomy surgery will be enrolled.

Timeline

Start date
2018-09-25
Primary completion
2022-11-11
Completion
2022-11-11
First posted
2018-08-15
Last updated
2022-11-16

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03631680. Inclusion in this directory is not an endorsement.